Faisal Khurshid
Stock Analyst at Leerink Partners
(0.29)
# 2649
Out of 5,358 analysts
20
Total ratings
46.15%
Success rate
-5.42%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
IRWD Ironwood Pharmaceuti... | Maintains: Market Perform | 3 1 | 0.6 | 66.67% | 2 | Apr 14, 2025 | |
SYRE Spyre Therapeutics | Initiates Coverage On: Outperform | 45 | 16.95 | 165.49% | 1 | Apr 8, 2025 | |
NRIX Nurix Therapeutics | Initiates Coverage On: Market Perform | 16 | 12.78 | 25.2% | 1 | Mar 17, 2025 | |
STTK Shattuck Labs | Initiates Coverage On: Outperform | 4 | 1.14 | 250.88% | 1 | Mar 17, 2025 | |
PLRX Pliant Therapeutics | Downgrades: Market Perform | 33 2 | 1.62 | 23.46% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 16 | 5.38 | 197.4% | 1 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 60 60 | 47.64 | 25.94% | 2 | Dec 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 80 | 61.94 | 29.16% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 15 | 1.26 | 1090.48% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 7 | 7.06 | -0.85% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 45 | 18.53 | 142.85% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Market Perform | 24 | 27.75 | -13.51% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 7 | 1.59 | 340.25% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 8 | 4.38 | 82.65% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Outperform | 5 | 0.78 | 541.03% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Market Perform | 17 21 | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 11 | 3.43 | 220.7% | 1 | Mar 21, 2023 |